Khiron Life Scie Stock Price, News & Analysis

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) will hold a conference call on May 28, 2021, at 10:00 a.m. ET to discuss its first-quarter financial results for the period ending March 31, 2021. The call will feature presentations from CEO Alvaro Torres, CFO Joel Friedman, and Chairman Chris Naprawa, followed by a Q&A session. Khiron has also engaged Stonebridge Partners LLC for investor relations services at a fee of USD $5,000 per month, with mutual renewal options. For more details, visit investors.khiron.ca.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) has highlighted findings from Project Twenty21, the UK's largest observational study on medical cannabis, published in 'Psychopharmacology'. The study shows significant improvements in quality of life for patients with chronic conditions, including a 50% increase in self-reported health among participants. Over 900 patients have accessed legal medical cannabis, avoiding chronic pain and dependency on traditional drugs. Khiron aims to expand its initiatives to enhance patient access and continues to lead in cannabis education.

Khiron Life Sciences Corp. announced that its Chairman, Chris Naprawa, will present at Canaccord Genuity's 2021 Virtual Cannabis Conference on May 11, 2021, at 1:00 p.m. EDT. The company has seen a significant increase in prescription fills, with a 135% rise in Q1 2021 compared to 2020, largely due to newly introduced medical cannabis insurance in Colombia. Khiron has a strong market presence in Latin America and Europe, delivering its first EU-GMP certified medical cannabis shipment to Germany. For more details, visit investors.khiron.ca.

Khiron Life Sciences Corp. reported a 31% sequential growth in Q4 2020, with revenues reaching $2.5 million, driven by increased medical cannabis sales and normalized clinic operations. Medical cannabis insurance coverage in Colombia, effective December 2020, has significantly boosted growth, with 7,500 prescriptions filled in Q1 2021. The company maintains strong cash reserves of $21.6 million. Despite a net loss of $24 million for 2020, management remains optimistic about future growth in Latin America and Europe, with plans to expand clinic operations and product sales.

Khiron Life Sciences Corp. has achieved UK Continuing Professional Development (CPD) accreditation for its educational platform, Khiron Academy, enabling UK medical professionals to earn CPD credits through medical cannabis training. The company has partnered with Cellen Therapeutics to enhance patient access to cannabis education. To date, nearly 1,000 medical professionals in Latin America and the UK have completed training, leading to over 13,000 prescriptions issued by physicians trained by Khiron, reflecting a compound monthly growth rate of 50%.

Khiron Life Sciences Corp. has announced an operational update emphasizing its expansion in the UK medical cannabis market. Following a successful launch in Germany, the company plans to introduce Khiron 1/14, a high-CBD flower, for UK patients in Q2 2021. This product will complement its existing high-THC offering and aims to increase patient access through improved supply chains. Khiron is also enhancing its product portfolio by exporting additional cannabis-based medical products from Colombia, thereby improving availability for patients in the UK.

Khiron Life Sciences Corp. has successfully completed its first shipment of EU-GMP certified medical cannabis to Germany, targeting immediate access through its distribution partner Nimbus Health GmbH. The launch product, Khiron 1/14 high-CBD flower, aims to address medical needs such as anxiety, substance use disorder, and migraines. With a distribution network spanning over 300 pharmacies in Germany, Khiron is positioned to establish a significant market presence. The company's ongoing education efforts for physicians further enhance its strategy in this growing market.

Khiron Life Sciences Corp. announced the opening of two new satellite Zerenia™ clinics in Cali and Bucaramanga, Colombia, expanding its network to six clinics. This expansion follows a successful start to 2021, with paid prescriptions surpassing total prescriptions from 2020. The company plans to open additional satellite clinics throughout Colombia, enhancing patient access to medical cannabis. CEO Alvaro Torres aims to reach 1 million patients by 2024, leveraging positive feedback from existing clinics to support this growth.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) announced that CEO Alvaro Torres will participate in the Q1 Virtual Investor Summit from March 23-25, 2021. The company's presentation is scheduled for March 24 at 1:00 PM ET. The Investor Summit connects smallcap companies with investors and will feature over 100 companies and 300 institutional and retail investors. Khiron is a leading medical cannabis provider in Colombia and is set to expand its operations into Germany and Brazil this year.